Get the Stockscreener App
41.72
0.10%
0.04
After Hours:
41.72
Guardant Health Inc stock is traded at $41.72, with a volume of 2.55M.
It is up +0.10% in the last 24 hours and down -4.90% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$41.68
Open:
$42.03
24h Volume:
2.55M
Relative Volume:
1.11
Market Cap:
$5.80B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-9.8396
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
-10.95%
1M Performance:
-4.90%
6M Performance:
+45.82%
1Y Performance:
+114.61%
1-Day Range:
$41.10
$43.12
1-Week Range:
$38.86
$46.18
52-Week Range:
$20.14
$52.92
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
41.72 | 5.80B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
403.13 | 159.89B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.73 | 142.45B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
491.70 | 37.95B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
106.93 | 30.97B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
148.99 | 26.72B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health to Participate in Upcoming Investor ConferencesMay 8, 2025 - BioSpace
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year - 01net
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year | GH Stock News - GuruFocus
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GH Stock News - GuruFocus
Guardant Health (GH) Price Target Raised by Piper Sandler to $60 | GH Stock News - GuruFocus
Piper Sandler Boosts Guardant Health (GH) Price Target to $60 | - GuruFocus
Guardant Health (GH): Scotiabank Raises Price Target to $57.00 | - GuruFocus
Genomic Cancer Testing Market Grows with Advances in Precision - openPR.com
Scotiabank Increases Guardant Health (GH) Price Target After Strong Q1 Performance | GH Stock News - GuruFocus
Guardant Health, Inc. (NASDAQ:GH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$59.17 - Yahoo Finance
Decoding Guardant Health Inc (GH): A Strategic SWOT Insight - GuruFocus
Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue - Barchart.com
Guardant Health, Inc. (NASDAQ:GH) Q1 2025 Earnings Call Transcript - Insider Monkey
Morgan Stanley Raises Price Target on Guardant Health to $60 From $52, Keeps Overweight Rating - marketscreener.com
Guardant Health (GH) Price Target Boosted by BTIG to $65 Amid St - GuruFocus
Guardant Health stock soars to 52-week high of $52.49 By Investing.com - Investing.com India
Guardant Health Reports Strong Q1 Revenue Growth - TipRanks
Guardant Health (GH) Sees Target Price Raised by TD Securities | - GuruFocus
Stifel Raises Price Target for Guardant Health (GH) to $60 | GH Stock News - GuruFocus
Canaccord raises Guardant Health target to $65, maintains Buy By Investing.com - Investing.com Canada
Guardant Health (GH) Sees Price Target Raised by Canaccord Genui - GuruFocus
Guardant Health: Tailwinds Are Beginning To Impact The Financials (NASDAQ:GH) - Seeking Alpha
Guardant Health (GH) Sees Price Target Raised by Canaccord Genuity | GH Stock News - GuruFocus
Guardant Health (GH) Price Target Increased Amid Positive Moment - GuruFocus
Guardant Health (GH) Receives Price Target Boost from UBS | GH S - GuruFocus
Guardant Health (GH) Stock Target Price Raised by Barclays Analy - GuruFocus
Guardant Health (GH) Stock Target Price Raised by Barclays Analyst | GH Stock News - GuruFocus
Guardant Health (GH) Receives Price Target Increase from UBS | G - GuruFocus
Guardant Health stock soars to 52-week high of $52.49 - Investing.com
UBS Adjusts Guardant Health Price Target to $70 From $65, Maintains Buy Rating - marketscreener.com
Canaccord raises Guardant Health target to $65, maintains Buy - Investing.com
Guardant Health (GH) Price Target Boosted by BTIG to $65 Amid Strong Growth | GH Stock News - GuruFocus
Canaccord Increases Guardant Health (GH) Price Target to $65 | G - GuruFocus
Guardant Health Inc (GH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Barclays Lifts Guardant Health (GH) Price Target Amid Business G - GuruFocus
Earnings call transcript: Guardant Health Q1 2025 beats EPS forecast, revenue rises - Investing.com Nigeria
Guardant Health Q1 Adjusted Loss Widen, Revenue Rises; 2025 Revenue Guidance Raised - marketscreener.com
Guardant Health Inc (GH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Guardant Health Surpasses Q1 2025 Revenue ExpectationsNews and Statistics - IndexBox
Guardant Health: Q1 Earnings Snapshot - New Haven Register
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - BioSpace
Guardant Health up 4% on Q1 beats, 2025 guidance revenue raise - MSN
Guardant Health (GH) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Guardant Health, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:GH) - Seeking Alpha
Guardant Health Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Guardant Health, Inc. SEC 10-Q Report - TradingView
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):